MARKET

AVXL

AVXL

Anavex Life
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.01
-0.05
-0.38%
Opening 14:02 02/26 EST
OPEN
13.17
PREV CLOSE
13.06
HIGH
13.61
LOW
12.57
VOLUME
770.66K
TURNOVER
--
52 WEEK HIGH
28.70
52 WEEK LOW
2.200
MARKET CAP
904.04M
P/E (TTM)
-28.6312
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Rett Syndrome Treatment Market Global Development, Industry Trends, Demand and Growth Analysis and Forecasts 2020 to 2027 By Ameco Research
pune, India, Thu, 25 Feb 2021 00:29:30 / Comserve Inc. / -- Rett Syndrome Treatment market to help players in achieving a strong market position. Buyers of...
Comserve · 1d ago
Cantor Fitzgerald Remains a Buy on Anavex Life Sciences (AVXL)
Cantor Fitzgerald analyst Charles Duncan reiterated a Buy rating on Anavex Life Sciences (AVXL) yesterday and set a price target of $25.00. The company's
SmarterAnalyst · 2d ago
DJ Anavex Life Sciences Price Target Raised to $25.00/Share From $10.00 by Cantor Fitzgerald
Dow Jones · 2d ago
Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day®
Rare Disease Day® at NIH will be held virtually on Monday, March 1, 2021, from 10:30 a.m. to 5:30 p.m. ESTNEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical ...
GlobeNewswire · 4d ago
Top Wall Street analysts say buy stocks like Denny's and Cloudflare as economy reopens
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Shopify & GoDaddy
CNBC.com · 5d ago
Anavex Life Sciences To Participate In Precision In Clinical Trials Virtual Summit Feb. 24 At 3:35 p.m. EST
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for
Benzinga · 02/19 12:17
Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit
GlobeNewswire · 02/19 12:00
Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021
GlobeNewswire · 02/18 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVXL. Analyze the recent business situations of Anavex Life through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVXL stock price target is 15.20 with a high estimate of 20.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 120
Institutional Holdings: 17.22M
% Owned: 24.78%
Shares Outstanding: 69.49M
TypeInstitutionsShares
Increased
28
716.77K
New
23
1.22M
Decreased
24
627.45K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.32%
Pharmaceuticals & Medical Research
-0.76%
Key Executives
President/Chief Executive Officer/Secretary/Director
Christopher Missling
Chief Financial Officer/Treasurer
Sandra Boenisch
Independent Director
Peter Donhauser
Independent Director
Elliot Favus
Independent Director
Athanasios Skarpelos
Independent Director
Steffen Thomas
Independent Director
Claus van der Velden
  • Dividends
  • Splits
  • Insider Activity
No Data
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. Its research and development pipeline includes a clinical drug candidate and various compounds in different stages of pre-clinical study. Its product pipeline also includes ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. The Company's SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066 is a mixed sigma-1/sigma-2 ligand. As of September 30, 2016, the Company had not generated any revenues from its operations.

Webull offers kinds of Anavex Life Sciences Corp stock information, including NASDAQ:AVXL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVXL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVXL stock methods without spending real money on the virtual paper trading platform.